OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
Published: 27 Apr 2026
Author: Towards Healthcare
ModeX Therapeutics Inc. announced that the first participant has been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19.MDX2301 is a tetravalent bispecific antibody; it has the potential to neutralise all known variants of SARS-CoV-2.
The researcher's study has evaluated the safety and tolerability of MDX2301 administered via different routes in healthy volunteers and in adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared to conventional monoclonal antibodies.
According to Towards Healthcare, the Multispecific antibodies market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 8.66 billion in 2026 to approximately USD 29.28 billion by 2035, representing a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. Growth is driven by the increasing cancer incidence worldwide, and creating a robust environment for the multispecific engineering and bispecific antibody platforms has reduced manufacturing hurdles and improved therapeutic efficacy with significant potential for growth and innovation in the years to come.
About MDX2301
MDX2301 is a tetravalent bispecific antibody developed by ModeX Therapeutics, designed for the prevention of COVID-19. It has the potential to neutralise all known variants of SARS-CoV-2. The first participants have been dosed in a Phase 1 clinical trial evaluating its safety and tolerability in healthy adults and those at high risk for severe COVID-19.
The study is evaluating the safety and tolerability of MDX2301 administered via different routes in healthy volunteers and in adults at high risk for severe COVID-19.MDX2301 is designed to provide high potency and greater breadth compared to conventional monoclonal antibodies.
About ModeX Therapeutics
This biopharmaceutical company develops innovative multispecific biologics for cancer, immunology, and infectious diseases. These platforms unite the power of multiple biologics in a single molecule to create multispecific antibody therapeutics designed to address complex diseases.
The ModeX pipeline includes first-in-class candidates for oncology indications against both solid and hematologic tumours, autoimmune and immunological diseases, and for infectious disease indications against the most pressing viral threats.
A recent report by Towards Healthcare highlights that the Multispecific antibodies market is witnessing growth due to the rising prevalence of complex diseases, particularly cancer and autoimmune disorders, which necessitate more targeted and effective therapeutic approaches. The treatment of cancer and potentially other diseases offers substantial rewards for companies at the forefront of this transformative segment.
North America is currently the largest market for multispecific antibodies, reflecting a robust biopharmaceutical industry, significant R&D investments, and a high prevalence of target diseases.
The Asia-Pacific region is experiencing significant growth in the multispecific antibodies market, driven by the increasing demand for advanced biologics and the focus on complicated disorders.